US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
pharma · Body weight management · Acromegaly
Currus Biologics Pty
Camurus Pty Ltd
Currus Biologics Pty drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Melbourne, AU HQ
2021 Founded
11 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Melbourne, AU
- Founded
- 2021
- Employees
- 11
- Programs
- 1
- Drugs
- 5
- Patents
- 0
Currus Biologics Pty pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Currus Biologics Pty drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Currus Biologics Pty in public FDA and regional records. Mechanism: Somatostatin receptor 2 agonist.
- Mechanism
- Somatostatin receptor 2 agonist
-
octreotide
Systemic hormonal preparations (H01)Systemic hormonal preparations (H01) compound in Currus Biologics Pty's portfolio. Mechanism: Somatostatin receptor agonist.
- Mechanism
- Somatostatin receptor agonist
-
US regulatory status: approved. Molecular target: Somatostatin receptor.
- Target
- Somatostatin receptor
- Mechanism
- Somatostatin receptor agonist
-
semaglutide
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.
- Target
- Glucagon-like peptide 1 receptor
- Mechanism
- Glucagon-like peptide 1 receptor agonist